FDA grants Orphan Drug Designation to Iomab-B

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted orphan drug designation for Iomab-B, a radioimmunotherapeutic that conditions relapsed and refractory acute myeloid leukemia patients for a hematopoietic stem cell transplant. Actinium Pharmaceuticals Inc., iomab-B’s sponsor, plans to begin a phase III trial in 150 relapsed and refractory AML patients over the age of 55. Iomab-B is a radioimmunoconjugate consisting of BC8,...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

ā€œWe’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,ā€ said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center. 
Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login